Esther Rajavelu, CFO & CBO at Spero Therapeutics, Inc. (SPRO), sold 20,689 shares at $0.78 ($16K) on 2025-02-05, disclosed to the SEC on 2025-02-05.
Open-market sale of $16k SPRO by CFO & CBO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| SPRO | SELL | 2026-02-04 | $41K | — | Filing → |
| SPRO | SELL | 2025-11-12 | $191K | — | Filing → |
| SPRO | SELL | 2024-11-12 | $53K | — | Filing → |